Bruker's revenues have slid for two consecutive periods, not three, as was originally reported.
NEW YORK, Aug. 3 (GenomeWeb News) - Bruker BioSciences today said that second-quarter revenue increased 11.3 percent to $71.4 million. The growth included a 3.3 percent favorable currency effect.
Despite the year-over-year improvement, the Q2 sales represent the third consecutive sequential quarter in which revenues have fallen. Bruker had fourth quarter 2004 revenue of $85.8 million and first quarter 2005 revenue of $74.9 million.
Second-quarter sales in the firm's Bruker Daltonics business, which derives roughly 70 percent of its revenue from life science mass spectrometry systems, grew 7.1 percent to $37.4 million. Sales from Bruker's AXS business, which makes X-ray analysis equipment, swelled 16.4 percent to $34.1 million.
The firm's R&D spending rose to $11 million from $10.3 million year over year.
Bruker posted second-quarter net earnings of $300,000, or $0 per share, from a net loss of $4.4 million, or $.05 per share, in the same period last year.
As of June 30, Bruker listed cash and short-term investments of $92 million.